HalioDx

The company will use the money to continue development of its flagship Immunoscore colon cancer assay, among other things.

Companies are now expected to have their tests cleared by authorities for clinical use, and to bring their entire catalogs into line with the new regulations by May 2022.

The partners will jointly develop and commercialize gene expression assays to predict response to cancer immunotherapy, based on the nCounter platform.

The firm, HalioDx, was formed following the departure of Qiagen Marseille's executive team and all its employees. 

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.